Sanofi invests €170 million in vaccine production facility in France

pharmafield logo - pharma news

Sanofi is investing €170 million in expanding a vaccine manufacturing site in Val de Reuil, France. 
 
The new facility will allow Sanofi Pasteur, the vaccines global business unit of Sanofi, to expand supply of VaxigripTetra® to up to 70 countries in six continents. The new quadrivalent influenza vaccine contains two A strains and two B strains of influenza virus, as per the World Health Organization recommendation.

The new Val de Reuil facility will  be the only site of its kind in France and Sanofi Pasteur remains the sole influenza vaccine producer in the country.  
 
This investment is one of several major capital expenditures Sanofi has made in recent years to improve and expand its vaccine production capacities across France, the United States and Mexico.
 
Sanofi plans to complete the expansion by 2021, subject to relevant health authority approvals, and will begin producing vaccines in this new facility in 2022.  
 
Philippe Luscan, Executive Vice President, Global Industrial Affairs, Sanofi, said: “This project brings together the expertise of our people with our leading industrial know-how and illustrates our commitment to manufacturing excellence solutions. Our investment underlines Sanofi’s intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets.”